View in EDS PDF Full Text

Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.

Saved in:
Bibliographic Details
Title: Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.
Authors: Garinis, Angela C.1,2,3 garinis@ohsu.edu, Poling, Gayla L.4, Rubenstein, Ronald C.5, Konrad-Martin, Dawn1,2, Hullar, Timothy E.1,2, Baguley, David M.6,7, Burrows, Holly L.8, Chisholm, Jennifer A.9, Custer, Amy10, Dreisbach Hawe, Laura11, Hunter, Lisa L.12, Marras, Theodore K.13, Ortiz, Candice E.14, Petersen, Lucretia14, Steyger, Peter S.1,15, Winthrop, Kevin16, Zettner, Erika M.17, Clark, Khaya1,18,19, Hungerford, Michelle1, Vachhani, Jay J.1
Source: American Journal of Audiology. Oct2021, Vol. 30, p800-809. 10p. 3 Diagrams, 2 Charts.
Subject Terms: *Hearing disorders, Antibiotics, Tinnitus, Consensus (Social sciences), Intravenous therapy, Aminoglycosides, Vestibular apparatus diseases, Cystic fibrosis, Treatment effectiveness, Ototoxicity, Pseudomonas diseases, Research funding, Bacterial diseases, Disease management, Disease risk factors
Abstract: Purpose Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Audiology is the property of American Speech-Language-Hearing Association and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Education Research Complete
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: ehh
DbLabel: Education Research Complete
An: 152955768
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Garinis%2C+Angela+C%2E%22">Garinis, Angela C.</searchLink><relatesTo>1,2,3</relatesTo><i> garinis@ohsu.edu</i><br /><searchLink fieldCode="AR" term="%22Poling%2C+Gayla+L%2E%22">Poling, Gayla L.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Rubenstein%2C+Ronald+C%2E%22">Rubenstein, Ronald C.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Konrad-Martin%2C+Dawn%22">Konrad-Martin, Dawn</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Hullar%2C+Timothy+E%2E%22">Hullar, Timothy E.</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Baguley%2C+David+M%2E%22">Baguley, David M.</searchLink><relatesTo>6,7</relatesTo><br /><searchLink fieldCode="AR" term="%22Burrows%2C+Holly+L%2E%22">Burrows, Holly L.</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Chisholm%2C+Jennifer+A%2E%22">Chisholm, Jennifer A.</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Custer%2C+Amy%22">Custer, Amy</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Dreisbach+Hawe%2C+Laura%22">Dreisbach Hawe, Laura</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Hunter%2C+Lisa+L%2E%22">Hunter, Lisa L.</searchLink><relatesTo>12</relatesTo><br /><searchLink fieldCode="AR" term="%22Marras%2C+Theodore+K%2E%22">Marras, Theodore K.</searchLink><relatesTo>13</relatesTo><br /><searchLink fieldCode="AR" term="%22Ortiz%2C+Candice+E%2E%22">Ortiz, Candice E.</searchLink><relatesTo>14</relatesTo><br /><searchLink fieldCode="AR" term="%22Petersen%2C+Lucretia%22">Petersen, Lucretia</searchLink><relatesTo>14</relatesTo><br /><searchLink fieldCode="AR" term="%22Steyger%2C+Peter+S%2E%22">Steyger, Peter S.</searchLink><relatesTo>1,15</relatesTo><br /><searchLink fieldCode="AR" term="%22Winthrop%2C+Kevin%22">Winthrop, Kevin</searchLink><relatesTo>16</relatesTo><br /><searchLink fieldCode="AR" term="%22Zettner%2C+Erika+M%2E%22">Zettner, Erika M.</searchLink><relatesTo>17</relatesTo><br /><searchLink fieldCode="AR" term="%22Clark%2C+Khaya%22">Clark, Khaya</searchLink><relatesTo>1,18,19</relatesTo><br /><searchLink fieldCode="AR" term="%22Hungerford%2C+Michelle%22">Hungerford, Michelle</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Vachhani%2C+Jay+J%2E%22">Vachhani, Jay J.</searchLink><relatesTo>1</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22American+Journal+of+Audiology%22">American Journal of Audiology</searchLink>. Oct2021, Vol. 30, p800-809. 10p. 3 Diagrams, 2 Charts.
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: *<searchLink fieldCode="DE" term="%22Hearing+disorders%22">Hearing disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Antibiotics%22">Antibiotics</searchLink><br /><searchLink fieldCode="DE" term="%22Tinnitus%22">Tinnitus</searchLink><br /><searchLink fieldCode="DE" term="%22Consensus+%28Social+sciences%29%22">Consensus (Social sciences)</searchLink><br /><searchLink fieldCode="DE" term="%22Intravenous+therapy%22">Intravenous therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Aminoglycosides%22">Aminoglycosides</searchLink><br /><searchLink fieldCode="DE" term="%22Vestibular+apparatus+diseases%22">Vestibular apparatus diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Cystic+fibrosis%22">Cystic fibrosis</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Ototoxicity%22">Ototoxicity</searchLink><br /><searchLink fieldCode="DE" term="%22Pseudomonas+diseases%22">Pseudomonas diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Bacterial+diseases%22">Bacterial diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+management%22">Disease management</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+risk+factors%22">Disease risk factors</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Purpose Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of American Journal of Audiology is the property of American Speech-Language-Hearing Association and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=ehh&AN=152955768
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1044/2021_AJA-21-00031
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 800
    Subjects:
      – SubjectFull: Hearing disorders
        Type: general
      – SubjectFull: Antibiotics
        Type: general
      – SubjectFull: Tinnitus
        Type: general
      – SubjectFull: Consensus (Social sciences)
        Type: general
      – SubjectFull: Intravenous therapy
        Type: general
      – SubjectFull: Aminoglycosides
        Type: general
      – SubjectFull: Vestibular apparatus diseases
        Type: general
      – SubjectFull: Cystic fibrosis
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Ototoxicity
        Type: general
      – SubjectFull: Pseudomonas diseases
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Bacterial diseases
        Type: general
      – SubjectFull: Disease management
        Type: general
      – SubjectFull: Disease risk factors
        Type: general
    Titles:
      – TitleFull: Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Garinis, Angela C.
      – PersonEntity:
          Name:
            NameFull: Poling, Gayla L.
      – PersonEntity:
          Name:
            NameFull: Rubenstein, Ronald C.
      – PersonEntity:
          Name:
            NameFull: Konrad-Martin, Dawn
      – PersonEntity:
          Name:
            NameFull: Hullar, Timothy E.
      – PersonEntity:
          Name:
            NameFull: Baguley, David M.
      – PersonEntity:
          Name:
            NameFull: Burrows, Holly L.
      – PersonEntity:
          Name:
            NameFull: Chisholm, Jennifer A.
      – PersonEntity:
          Name:
            NameFull: Custer, Amy
      – PersonEntity:
          Name:
            NameFull: Dreisbach Hawe, Laura
      – PersonEntity:
          Name:
            NameFull: Hunter, Lisa L.
      – PersonEntity:
          Name:
            NameFull: Marras, Theodore K.
      – PersonEntity:
          Name:
            NameFull: Ortiz, Candice E.
      – PersonEntity:
          Name:
            NameFull: Petersen, Lucretia
      – PersonEntity:
          Name:
            NameFull: Steyger, Peter S.
      – PersonEntity:
          Name:
            NameFull: Winthrop, Kevin
      – PersonEntity:
          Name:
            NameFull: Zettner, Erika M.
      – PersonEntity:
          Name:
            NameFull: Clark, Khaya
      – PersonEntity:
          Name:
            NameFull: Hungerford, Michelle
      – PersonEntity:
          Name:
            NameFull: Vachhani, Jay J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2021
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 10590889
          Numbering:
            – Type: volume
              Value: 30
          Titles:
            – TitleFull: American Journal of Audiology
              Type: main
ResultId 1